» Articles » PMID: 35321771

Short to Midterm Follow-up of Multi-system Inflammatory Syndrome in Children with Special Reference to Cardiac Involvement

Overview
Journal Cardiol Young
Date 2022 Mar 24
PMID 35321771
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: We aim to describe the early and upto 16 months follow-up of post-coronavirus disease (COVID), multi-system inflammatory syndrome in children (MIS-C), with special reference to cardiac involvement.

Study Design: This cohort non-interventional descriptive study included patients <18 years admitted between May, 2020 and April, 2021. Based on underlying similarities, children were classified as post-COVID MIS-C with overlapping Kawasaki Disease, MIS-C with no overlapping Kawasaki Disease, and MIS-C with shock. Post-discharge, patients were followed at 1, 3, 6, 12, and 16 months.

Results: Forty-one patients predominantly males (73%), at median age of 7 years (range 0.2-16 years) fulfilled the World Health Organisation criteria for MIS-C. Cardiac involvement was seen in 15 (36.5%); impaired left ventricle (LV) function in 5 (12.2%), coronary artery involvement in 10 (24.4%), pericardial effusion in 6 (14.6%) patients, and no arrhythmias. There were two hospital deaths (4.9%), both in MIS-C shock subgroup (2/10, 20%). At 1 month, there was persistent LV dysfunction in 2/5, coronary artery abnormalities in 7/10, and pericardial effusion resolved completely in all patients. By 6 months, LV function returned to normal in all but coronary abnormalities persisted in two patients. At last follow-up (median 9.8 months, interquartile range 2-16 months), in 36/38 (94.7%) patients, coronary artery dilatation was persistent in 2 (20%) patients.

Conclusions: Children with MIS-C have a good early outcome, though MIS-C with shock can be life-threatening subgroup in a resource-constrained country setting. On midterm follow-up, there is normalisation of LV function in all and recovery of coronary abnormalities in 80% of patients.

Citing Articles

In-hospital unfavorable outcomes of MIS-C during 2020-2022: a systematic review.

Alvarado-Gamarra G, Alcala-Marcos K, Balmaceda-Nieto P, Visconti-Lopez F, Torres-Balarezo P, Moran-Marinos C Eur J Pediatr. 2024; 183(12):5071-5084.

PMID: 39349752 DOI: 10.1007/s00431-024-05787-x.


Long-term health outcome and quality of life in children with multisystem inflammatory syndrome: findings from multidisciplinary follow-up at an Italian tertiary-care paediatric hospital.

DAuria E, Bova S, Dallapiccola A, De Santis R, Leone A, Calcaterra V Eur J Pediatr. 2024; 183(11):4885-4895.

PMID: 39256240 PMC: 11473591. DOI: 10.1007/s00431-024-05706-0.


Short-, mid-, and long-term complications after multisystem inflammatory syndrome in children over a 24-month follow-up period in a hospital in Lima-Peru, 2020-2022.

Alvarado-Gamarra G, Estupinan-Vigil M, Garces-Ghilardi R, Dominguez-Rojas J, Del Aguila O, Alcala-Marcos K Front Pediatr. 2023; 11:1232522.

PMID: 38078321 PMC: 10710304. DOI: 10.3389/fped.2023.1232522.


Outpatient Pediatric Cardiology Follow-Up of Patients with Multisystem Inflammatory Syndrome in Children (MIS-C): A Single-Institution, Medium-Term Follow-Up Study.

Jose J, Tierney E Pediatr Cardiol. 2023; 45(2):401-409.

PMID: 37749261 DOI: 10.1007/s00246-023-03298-4.


Complete Kawasaki disease after COVID-19 infection in an infant.

Tahir M, Mehmood R, Ahmad M Pak J Med Sci. 2023; 39(2):616-618.

PMID: 36950447 PMC: 10025724. DOI: 10.12669/pjms.39.2.6359.